Cancer de la prostate localement avancé et hormonothérapie

25 mars 2010

Auteurs : D. Rossi, P. Beuzeboc, F. Staerman, M.-O. Timsit, A. Benchikh El Fegoun
Référence : Prog Urol, 2010, 20, S68, suppl. S1


Le texte complet de cet article est disponible en PDF.
Cliquer ici pour le visualiser


Rogers C.G., Khan M.A., Craig Miller M., Veltri R.W., Partin A.W. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy Cancer 2004 ;  101 : 2549-2556 [cross-ref]
Wirth M.P., Weissbach L., Marx F.J., Heckl W., Jellinghaus W., Riedmiller H., et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer Eur Urol 2004 ;  45 : 267-270discussion 70.
McLeod D.G., Iversen P., See W.A., Morris T., Armstrong J., Wirth M.P. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer BJU Int 2006 ;  97 : 247-254 [cross-ref]
Nyman C.R., Andersen J.T., Lodding P., Sandin T., Varenhorst E. The patient’s choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin- releasing hormone analogue or orchidectomy BJU Int 2005 ;  96 : 1014-1018 [cross-ref]
Boustead G., Edwards S.J. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials BJU Int 2007 ;  99 : 1383-1389 [cross-ref]
Swanson G.P., Hussey M.A., Tangen C.M., Chin J., Messing E., Canby-Hagino E., et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794 J Clin Oncol 2007 ;  25 : 2225-2229 [cross-ref]
Ganswindt U., Stenzl A., Bamberg M., Belka C. Adjuvant radiotherapy for patients with locally advanced prostate cancer-a new standard? Eur Urol 2008 ;  54 : 528-542 [cross-ref]
Partin A.W., Kattan M.W., Subong E.N., Walsh P.C., Wojno K.J., Oesterling J.E., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update JAMA 1997 ;  277 : 1445-1451 [cross-ref]
Samson D.J., Seidenfeld J., Schmitt B., Hasselblad V., Albertsen P.C., Bennett C.L., et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma Cancer 2002 ;  95 : 361-376 [cross-ref]
Schmitt B., Wilt T.J., Schellhammer P.F., DeMasi V., Sartor O., Crawford E.D., et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review Urology 2001 ;  57 : 727-732 [inter-ref]
Bubley G.J. Is the flare phenomenon clinically significant? Urology 2001 ;  58 : 5-9 [inter-ref]
Serretta V., Daricello G., Dispensa N., Allegro R., Pavone C., Pavone-Macaluso M. Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study BJU Int 2003 ;  92 : 545-549discussion 9-50.
Kawakami J., Cowan J.E., Elkin E.P., Latini D.M., DuChane J., Carroll P.R. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) Cancer 2006 ;  106 : 1708-1714 [cross-ref]
Boccon-Gibod L., Bertaccini A., Bono A.V., Dev Sarmah B., Holtl W., Mottet N., et al. Management of locally advanced prostate cancer: a European consensus Int J Clin Pract 2003 ;  57 : 187-194
Roach M., DeSilvio M., Lawton C., Uhl V., Machtay M., Seider M.J., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 2003 ;  21 : 1904-1911 [cross-ref]
Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 2002 ;  360 : 103-106 [cross-ref]
Pilepich M.V., Winter K., Lawton C.A., Krisch R.E., Wolkov H.B., Movsas B., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 2005 ;  61 : 1285-1290 [cross-ref]
Kirby R., Robertson C., Turkes A., Griffiths K., Denis L.J., Boyle P., et al. Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group Prostate 1999 ;  40 : 105-114 [cross-ref]
Oh W.K., Manola J., Bittmann L., Brufsky A., Kaplan I.D., Smith M.R., et al. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up Urology 2003 ;  62 : 99-104 [inter-ref]
Calais da Silva F.E., Bono A.V., Whelan P., Brausi M., Marques Queimadelos A., Martin J.A., et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 2009 ;  55 : 1269-1277 [cross-ref]
Schroder F.H., Whelan P., de Reijke T.M., Kurth K.H., Pavone-Macaluso M., Mattelaer J., et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the “European Organization for Research and Treatment of Cancer” (EORTC) Protocol 30892 Eur Urol 2004 ;  45 : 457-464 [cross-ref]
Joyce R., Fenton M.A., Rode P., Constantine M., Gaynes L., Kolvenbag G., et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy J Urol 1998 ;  159 : 149-153 [cross-ref]
Kelly W.K., Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome J Urol 1993 ;  149 : 607-609 [cross-ref]
Scher H.I., Beer T.M., Higano C.S., Logothetis C., Anand A., Hirmand M., et al. Phase I-II study of MDV3100 in castration-resistant prostate cancer (CRPC) J Clin Oncol 2009 ;  27 : abstract 151.
Reid A.H., Attard G., Danila D., Ryan C.J., Thompson E., Kheoh T., et al. A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts) J Clin Oncol 2009 ;  27 : abstract 5047.

© 2010 
Elsevier Masson SAS. Tous droits réservés.